F.D.A. Requests Federal Investigation of Alzheimer’s Drug Approval

The agency’s acting head said a review should look into whether any interactions between agency staff and the drug developer, Biogen, broke F.D.A. rules.

View original article
Contributor: Rebecca Robbins